Perampanel exhibits anticonvulsant action against pentylentetrazol-induced seizures in immature rats

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985823%3A_____%2F21%3A00541569" target="_blank" >RIV/67985823:_____/21:00541569 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/j.eplepsyres.2020.106523" target="_blank" >https://doi.org/10.1016/j.eplepsyres.2020.106523</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.eplepsyres.2020.106523" target="_blank" >10.1016/j.eplepsyres.2020.106523</a>

Result language
angličtina
Original language name
Perampanel exhibits anticonvulsant action against pentylentetrazol-induced seizures in immature rats
Original language description
Perampanel is a new antiepileptic drug with unique mechanism of action - antagonism of AMPA receptors. Its action in immature animals is not yet sufficiently known therefore we started to study anticonvulsant action of perampanel pretreatment (1-20 mg/kg i.p.) against seizures elicited by pentylenetetrazol. Three age groups of rats were examined - 12, 18 and 25 days old. Perampanel selectively suppressed the tonic phase of generalized seizures in the two younger groups and whole tonic-clonic seizures in the 25-day-old group. It exhibited also an anticonvulsant action against minimal clonic seizures present in control 18- and 25-day-old rats.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)